View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The FDA has cleared an app for the Apple Watch to help people suffering from nightmares or post-traumatic stress disorder get a better night’s sleep. Our goal with LIMITx is to develop a treatment for effective pain relief at a one or two tablet dose while providing overdose protection by limiting high peak levels of drug in the bloodstream (Cmax) that can lead to respiratory depression and death when more than the recommended dose is ingested.

The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

Find the latest ACURA PHARMACEUTICALS INC (ACUR) stock quote, history, news and other vital information to help you with your stock trading and investing. (AstraZeneca/Herzog & DeMeuron), Case Study | Bioclinica Rescues a Study in Jeopardy with a Comprehensive Clinical Adjudication Solution. Receive a free world-class investing education from MarketBeat. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

Acerta News.

Back in 2015, AstraZeneca bought a majority stake in blood cancer biotech Acerta for $4 billion. Calquence significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia, June 6, 2019 AstraZeneca admitted that some early data for Acerta's acalabrutinib was crooked.

Horton (NYSE: DHI) is Safe Play in Hot Sector, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, 8 Stocks That Robinhood Investors Got Right, 7 Stocks That Will Help You Forget About the Fed, Receive Analysts' Upgrades and Downgrades Daily. The Parties are in negotiations to amend the AD Pharma Agreement to extend the date of the FDA acceptance of the NDA for LTX-03 which would allow for these unforeseen delays, although no guarantee can be given that these negotiations will be successful. Only 0.02% of the stock of Acerus Pharmaceuticals is held by institutions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ll rights reserved. Export data to Excel for your own analysis.

View our full suite of financial calendars and market data tables, all for free. Culture & Values [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![])+(+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![])+(+!![]))/+((!+[]+(!![])+!![]+[])+(+!![])+(!+[]+(!![])+!![]+!![]+!![])+(+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])-[])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!! In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. CALQUENCE Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early, March 28, 2019

Advanced Stock Screeners and Research Tools.

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

Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia, June 15, 2019

Acerus Pharmaceuticals has a market capitalization of $5.17 million and generates $7.38 million in revenue each year. Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9.

Get short term trading ideas from the MarketBeat Idea Engine. It blamed a “former Acerta employee who acted alone to falsify a preclinical data set provided through external collaborations,” according to a statement reported by Retraction Watch.

AD Pharma has deferred the remittance of the required monthly license payments for May, June, July and August, 2020 pending the completion of these negotiations.About Acura Pharmaceuticals Acura Pharmaceuticals is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. Analysis of forensic data associated with hydrocodone overdose death suggests a typical consumption of approximately 16 immediate-release tablets, well within the number of tablets in an average filled opioid prescription.

Hydrocodone with acetaminophen remains the single largest prescribed opioid in the U.S. with excess oral ingestion as the most prevalent method of misuse. A company was facing major challenges in a global clinical trial program with 30 studies for an uncommon indication. AstraZeneca added: “It’s important to note that this isolated issue had no impact on the integrity of acalabrutinib data in any clinical trials, and there was no risk to patient health.”.

LIMITx™ Technology utilizes acid neutralizing ingredients to precisely control gastric acidity, which limits the release of drug from tablets and its subsequent systemic absorption when multiple tablets are ingested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arketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis.

Subscribe to Premium to view Fair Value for ACUR, Amendment Extends NDA Acceptance Date and Expands AgreementPALATINE, Ill., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”), expand the product licenses, and revise the license payment schedule. © American Consumer News, LLC dba MarketBeat® 2010-2020.

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) released its quarterly earnings results on Monday, November, 5th. Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma, May 7, 2019 Identify stocks that meet your criteria using seven unique stock screeners.

Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Forward-looking statements may include, but are not limited to: * our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our LIMITx and IMPEDE technologies; * whether we will receive FDA acceptance for an NDA for LTX-03 by the target date; * whether our licensees will terminate the license prior to commercialization; * the expected results of clinical studies relating to LTX-03 or any successor product candidate, the date by which such studies will complete and the results will be available and whether any product candidate will ultimately receive FDA approval; * the ability of LTX-03 single tablets to achieve bioequivalence or to demonstrate efficacy in a clinical study; * whether our licensing partners will develop any additional products and utilize Acura for such development; * whether LIMITx will retard the release of opioid active ingredients as dose levels increase; * whether the extent to which products formulated with the LIMITx technology mitigate respiratory depression risk will be determined sufficient by the FDA; * our and our licensee’s ability to successfully launch and commercialize our products and technologies; * our and our licensee’s ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies; * the market acceptance of, timing of commercial launch and competitive environment for any of our products; * our ability to develop and enter into additional license agreements for our product candidates using our technologies; * the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties; * the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation; * the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support an NDA and FDA approval of our product candidates; * changes in regulatory requirements; * adverse safety findings relating to our commercialized products or product candidates in development; * whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our technologies; and * whether our product candidates will ultimately perform as intended in commercial settings.